Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2 V617F and Development of Myeloproliferative Neoplasms

被引：0

作者：

Nangalia, Jyoti ^{[1
]}

Guo, Jing ^{[1
]}

Walter, Klaudia ^{[1
]}

Quiros, Pedro ^{[2
]}

Gu, Muxin ^{[2
]}

Baxter, E. Joanna ^{[3
]}

Danesh, John ^{[4
]}

Di Angelantonio, Emanuele ^{[4
]}

Roberts, David ^{[4
]}

Guglielmelli, Paola ^{[5
,6
]}

Harrison, Claire N. ^{[7
]}

Godfrey, Anna L. ^{[8
]}

Green, Anthony R. ^{[9
]}

Vassiliou, George ^{[9
]}

Vuckovic, Dragana ^{[10
]}

Soranzo, Nicole ^{[11
,12
]}

机构：

[1] Wellcome Sanger Inst, Hinxton, England

[2] Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[3] Cambridge Univ Hosp NHS Fdn Trust, Dept Haematol, Cambridge, England

[4] Univ Cambridge, Natl Inst Hlth Res, Blood & Transplant Res Unit Donor Hlth & Gen, Cambridge, England

[5] AOU Careggi, Centro Ric & Innovazione Malattie Mieloproliferat, Florence, Italy

[6] Univ Florence, Dept Expt & Clin Med, Florence, Italy

[7] Guys & St Thomas NHS Fdn Trust, London, England

[8] Cambridge Univ Hosp NHS Trust, Cambridge, England

[9] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[10] Imperial Coll London, London, England

[11] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England

[12] Human Technopole, Milan, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189551

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] JAK-STAT PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS: FROM JAK2 V617F TO CALRETICULIN MUTANTS
Constantinescu, S. N.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 31 - 31
[22] Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
Cheng, Zhiyong
Fu, Jianzhu
Liu, Guimin
Zhang, Lijun
Xu, Qian
Wang, Su-yun
LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 196 - 203
[23] No evidence for amplification of V617F JAK2 in myeloproliferative disorders
Jones, A. V.
Bunyan, D. J.
LEUKEMIA, 2007, 21 (12) : 2561 - 2563
[24] No evidence for amplification of V617F JAK2 in myeloproliferative disorders
A V Jones
D J Bunyan
N C P Cross
Leukemia, 2007, 21 : 2561 - 2563
[25] JAK2 V617F: implications for thrombosis in myeloproliferative diseases
Hexner, Elizabeth O.
CURRENT OPINION IN HEMATOLOGY, 2007, 14 (05) : 450 - 454
[26] Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype
Cross, Nicholas C. P.
Jones, Amy V.
Silver, Richard T.
Oscier, David
Metzgeroth, Georgia
Wang, Y. Lynn
Collins, Andrew
Reiter, Andreas
Grand, Francis
Chase, Andrew
BLOOD, 2008, 112 (11) : 71 - 71
[27] The clinical value of plasma CFDNA JAK2 V617F mutation detection in myeloproliferative neoplasms
Wu, Q.
Cao, G.
Guan, M.
CLINICA CHIMICA ACTA, 2024, 558
[28] Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm
Fleischman, Angela G.
Aichberger, Karl J.
Petersen, Curtis L.
Doratotaj, Shirin
Bumm, Thomas G.
Pahl, Heike L.
Druker, Brian J.
Deininger, Michael W.
BLOOD, 2010, 116 (21) : 348 - 348
[29] CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
Tanja Belcic Mikic
Tadej Pajic
Matjaz Sever
Scientific Reports, 9
[30] Correlation of JAK2 V617F Mutation Burden with Clinical and Hematologic Characteristics of Myeloproliferative Neoplasms
Brown, A. F.
Wang, Y.
Abu-Ghusson, M. M.
George, P. A.
Vadlamudi, K.
Furmaga, W. B.
Fan, H.
MODERN PATHOLOGY, 2013, 26 : 321A - 321A

← 1 2 3 4 5 →